INT33099

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 1985
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 32
Total Number 33
Disease Relevance 13.82
Pain Relevance 9.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
caudate nucleus 2
platelet 2
putamen 2
somatic cells 1
globus pallidus 1
INSRR (Homo sapiens)
Pain Link Frequency Relevance Heat
opioid receptor 57 100.00 Very High Very High Very High
Cannabinoid 20 100.00 Very High Very High Very High
antagonist 16 100.00 Very High Very High Very High
adenocard 15 100.00 Very High Very High Very High
Dopamine 15 100.00 Very High Very High Very High
nMDA receptor antagonist 1 100.00 Very High Very High Very High
Immobilon 6 99.82 Very High Very High Very High
Opioid 7 99.72 Very High Very High Very High
Dorsal horn 1 99.68 Very High Very High Very High
Pain 18 99.48 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 268 99.76 Very High Very High Very High
Motor Neuron Diseases 4 99.62 Very High Very High Very High
Pain 16 99.48 Very High Very High Very High
Disease 107 99.18 Very High Very High Very High
Hyperalgesia 23 98.52 Very High Very High Very High
Pressure And Volume Under Development 4 98.46 Very High Very High Very High
Solid Tumor 5 98.16 Very High Very High Very High
Diuresis 5 98.12 Very High Very High Very High
Rhinitis 1 98.02 Very High Very High Very High
Headache 2 97.82 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In some cases, decreased peripheral BDZ receptor density in lymphocytes has been showed to be paralleled by similar changes in mRNA levels (Rocca et al 1991; Nudmamud et al 2000).
Negative_regulation (decreased) of BDZ receptor in lymphocytes
1) Confidence 0.40 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2413195 Disease Relevance 0.63 Pain Relevance 0.04
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor in caudate nucleus associated with gaba, adenocard, dopamine, cannabinoid and disease
2) Confidence 0.27 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.58 Pain Relevance 0.55
Second, intermediate neuropathological grades (grades 1, 2) showed a further marked decrease of CB(1) receptor binding in the caudate nucleus and putamen; this was associated with a loss of D(1) receptors in the caudate nucleus and putamen and a loss of both CB(1) and D(1) receptors in the substantia nigra.
Negative_regulation (decrease) of ) receptor in putamen associated with substantia nigra
3) Confidence 0.27 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.55 Pain Relevance 0.61
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor in globus pallidus associated with gaba, adenocard, dopamine, cannabinoid and disease
4) Confidence 0.09 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.58 Pain Relevance 0.55
Second, intermediate neuropathological grades (grades 1, 2) showed a further marked decrease of CB(1) receptor binding in the caudate nucleus and putamen; this was associated with a loss of D(1) receptors in the caudate nucleus and putamen and a loss of both CB(1) and D(1) receptors in the substantia nigra.
Negative_regulation (decrease) of ) receptor in caudate nucleus associated with substantia nigra
5) Confidence 0.09 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.55 Pain Relevance 0.61
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor in putamen associated with gaba, adenocard, dopamine, cannabinoid and disease
6) Confidence 0.09 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.58 Pain Relevance 0.55
Absence of classical opioid receptor on human mononuclear cells.
Negative_regulation (Absence) of receptor in mononuclear cells associated with opioid receptor
7) Confidence 0.05 Published 1985 Journal J Clin Lab Immunol Section Title Doc Link 2993625 Disease Relevance 0 Pain Relevance 0.76
In ALS cases, muscarinic receptor binding sites were markedly reduced in motor neuron areas and slightly reduced in the dorsal horn, while the other binding sites studied were relatively unchanged.
Negative_regulation (reduced) of receptor in motor neuron associated with dorsal horn and motor neuron diseases
8) Confidence 0.05 Published 1985 Journal Acta Neurol. Scand. Section Abstract Doc Link 2998142 Disease Relevance 0.34 Pain Relevance 0.34
PERSPECTIVE: This article presents the antihyperalgesic effect of CHF3381, a new NMDA receptor antagonist and reversible MAO-A inhibitor, in a human pain model and might guide the proper selection of CHF3381 doses to be used in Phase 2 studies in patients with neuropathic pain.
Negative_regulation (inhibitor) of receptor associated with pain, antihyperalgesic, nmda receptor antagonist and neuropathic pain
9) Confidence 0.03 Published 2006 Journal J Pain Section Abstract Doc Link 16885013 Disease Relevance 1.06 Pain Relevance 1.40
This study is the first report identifying several negative residues in the P2X(3) receptor ectodomain differentially contributing to the general process of receptor desensitization.
Negative_regulation (desensitization) of receptor
10) Confidence 0.03 Published 2004 Journal J. Biol. Chem. Section Abstract Doc Link 15475563 Disease Relevance 0 Pain Relevance 0.03
The variability of in vivo potency and efficacy of the NK(1) receptor antagonists in the mechanical hyperalgesia model is difficult to interpret as all compounds are highly effective at blocking the NK(1) receptor in guinea-pig tissues.
Negative_regulation (blocking) of receptor associated with hyperalgesia, antagonist and potency
11) Confidence 0.01 Published 2000 Journal Pain Section Abstract Doc Link 10963905 Disease Relevance 0.77 Pain Relevance 0.83
This phenomenon may limit the impact of exclusively targeting EGFR and c-erbB2 proteins, and may explain the acquired resistance to anticancer drugs that inhibit receptor tyrosine kinases [61].
Negative_regulation (inhibit) of receptor
12) Confidence 0.01 Published 2010 Journal Diagn Pathol Section Body Doc Link PMC2859381 Disease Relevance 0.52 Pain Relevance 0
This dual effect was found to depend on the activation / inactivation of Receptor Ck.
Negative_regulation (inactivation) of Receptor
13) Confidence 0.01 Published 2006 Journal BMC Cell Biol Section Body Doc Link PMC1351175 Disease Relevance 0.30 Pain Relevance 0.07
GP IIb-IIIa has a narrow tissue distribution, being found only on platelets and their progenitors, and inhibition of its receptor function has emerged as a promising new therapeutic strategy for management of acute ischemic coronary syndromes and acute ischemic complications of percutaneous coronary interventions.
Negative_regulation (inhibition) of receptor in platelets associated with syndrome
14) Confidence 0.01 Published 1997 Journal Am. J. Cardiol. Section Abstract Doc Link 9291241 Disease Relevance 0.29 Pain Relevance 0
Like barbourin, eptifibatide is a specific and robust inhibitor of the GP IIb-IIIa receptor function, having a low affinity for other integrins and strongly preventing platelet aggregation.
Negative_regulation (inhibitor) of receptor in platelet
15) Confidence 0.01 Published 1997 Journal Am. J. Cardiol. Section Abstract Doc Link 9291241 Disease Relevance 0.40 Pain Relevance 0.03
Pretreatment of these cells with SNC-80 (100 nM) for 24 hr produced 1) a time-dependent reduction of delta receptor density, as measured by radioligand binding studies with [3H]naltrindole; 2) a shift in the EC50 value of SNC-80 from 7.7 +/- 4.2 nM to 44.1 +/- 12 nM, as measured by the cyclic AMP assay; 3) a reduction in the maximum inhibition of adenylyl cyclase activity from 86% to 48%; 4) a marked increase in the forskolin stimulation of basal cyclic AMP accumulation by nearly 100% (from 442 pmol/mg of protein to 824 pmol/mg of protein); and 5) a 5-fold increase in forskolin-stimulated cyclic AMP accumulation after addition of naltrindole.
Negative_regulation (reduction) of receptor
16) Confidence 0.01 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8819489 Disease Relevance 0 Pain Relevance 0.52
Similar down-regulation of this receptor has been described in animal studies [34] and this phenomenon may be important for progression of normal labor.
Negative_regulation (regulation) of receptor
17) Confidence 0.01 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1513580 Disease Relevance 0.09 Pain Relevance 0.03
The reduction of the receptor level with 1 microM betaFNA significantly increased the rate of etorphine-induced receptor desensitization.
Negative_regulation (reduction) of receptor associated with immobilon
18) Confidence 0.01 Published 2000 Journal Mol. Pharmacol. Section Abstract Doc Link 10908307 Disease Relevance 0.06 Pain Relevance 0.42
In this study, we demonstrated the relatively slow rate of receptor desensitization could be attributed partially to the recycling of internalized receptor as determined by fluorescence-activated cell-sorting analysis.
Negative_regulation (desensitization) of receptor
19) Confidence 0.01 Published 2000 Journal Mol. Pharmacol. Section Abstract Doc Link 10908307 Disease Relevance 0 Pain Relevance 0.32
The reduction of the receptor level with 1 microM betaFNA significantly increased the rate of etorphine-induced receptor desensitization.
Negative_regulation (desensitization) of receptor associated with immobilon
20) Confidence 0.01 Published 2000 Journal Mol. Pharmacol. Section Abstract Doc Link 10908307 Disease Relevance 0.07 Pain Relevance 0.42

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox